ArticleAdvances in experimental medicine and biology2021
Human Papillomavirus-Associated Cancers.
Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- The role of human papillomavirus in oral squamous cell and verrucous carcinomas: a systematic review with case series.Oncology reviews · 2026Pooled it
- Costs of human papillomavirus vaccine delivery in low- and middle-income countries: A systematic review.Vaccine · 2024Pooled it
- An updated systemic review and meta-analysis on human papillomavirus in breast carcinogenesis.Frontiers in oncology · 2023Pooled it
- Primary Pap Smear Cytological Diagnosis of ASC-US: HR-HPV Genotyping and Follow-Up of HPV-Positive Patients.Cancers · 2026Article
- Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes.Diseases (Basel, Switzerland) · 2026Review
- Pesticide Exposure and Gynecological Cancers: A Review of Epidemiological Evidence and Mechanistic Pathways.Diseases (Basel, Switzerland) · 2026Review
- A low-dose self-amplifying mRNA vaccine encoding HPV16 E6/E7 induces potent T-cell immunity and antitumor protection in mice.Cancer immunology, immunotherapy : CII · 2026Article
- Bridging the service gap: health facility challenges in HPV vaccine uptake in rural Uganda.BMC women's health · 2026Article
- Comparative Analysis of Transcription Factor Binding Sites in the Long Control Region Across Human Papillomavirus Types.Viruses · 2026Article
- Epidemiologic burden, clinical attribution, and implications for immunization strategies of HPV infection among males in Sichuan, China: a large-sample cross-sectional study.Virology journal · 2026Article
- Determination of Human Papillomavirus prevalence in the female population from Zanjan, Iran.Preventive medicine reports · 2026Article
- Revisiting HPV vaccination post-COVID: geopolitical, sociocultural, and ethical disparities in global health.International journal for equity in health · 2025Review
- Analysis of divergent gene expression between HPV + and HPV- head and neck squamous cell carcinoma patients.Infectious agents and cancer · 2025Article
- Role of L1 HPV Protein Expression in the Cytological Diagnosis of Precancerous Cervical Lesions.Journal of clinical medicine · 2025Review
- The viral landscape in metastatic solid cancers.Heliyon · 2025Article
- Article
- Human Papillomavirus (HPV) Vaccination: Progress, Challenges, and Future Directions in Global Immunization Strategies.Vaccines · 2024Review
- Human Papillomavirus-Related Cancer Vaccine Strategies.Vaccines · 2024Review
- Characterization of multiple human papillomavirus types in the human vagina following ovarian hormonal stimulation.Virology journal · 2024Article
- VaxBot-HPV: A GPT-based Chatbot for Answering HPV Vaccine-related Questions.Research square · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human Papillomavirus (HPV) is the causative agent in the majority of anal, head and neck, oral, oropharyngeal, penile, vaginal, vulvar, and cervical cancers. Cervical cancer is the fourth most common cancer among women worldwide. Of all diagnosed human malignant neoplasms, approximately 4.5% are attributable to HPV, including cervical, anal cancers, vaginal, vulvar, penile, and oropharyngeal cancers. Over 182 HPV types have been identified and sequenced to date however, only certain types of HPV are more frequent in malignant lesions and considered to be a major risk factor in the development of some cancers. Because most HPV infections are transient, and an individual's immunocompetent may clear the infection, HPV infection has received little attention from clinicians, the general public, or policy makers. This lack of attention may underpin a deadly and increasing problem because each newly acquired infection has the potential to persist and become an incurable, lifelong affliction. In addition, no successful treatment of HPV infection currently exists despite the great strides toward understanding the mechanisms underlying HPV pathogenesis. Moreover, ample research has proven that the use of prophylactic vaccines, such as Gardasil and Cervarix, have led to documented progress in decreasing the burden of HPV infection, however not all countries introduced a government-funded National HPV Vaccination Program to protect young men and women. This chapter summarizes the HPV infection, detection and prevention. We also shed light on non-cervical HPV-related cancers, which is rapidly increasing in more developed countries toward cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.